

# NEW ZEALAND DATA SHEET

## 1. PRODUCT NAME

SPINRAZA nusinersen solution for injection 12 mg/5 mL.

## 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each single-use vial contains 12.6 mg of nusinersen heptadecasodium equivalent to 12 mg of nusinersen as the free acid (or 2.4 mg/mL) in artificial cerebrospinal fluid.

For the full list of excipients, see section 6.1.

## 3. PHARMACEUTICAL FORM

Solution for injection.

Sterile, preservative-free, clear to colourless isotonic solution, practically free from visible particles, with pH of approximately 7.2.

## 4. CLINICAL PARTICULARS

### 4.1 Therapeutic indications

SPINRAZA is indicated for the treatment of 5q Spinal Muscular Atrophy (SMA).

### 4.2 Dose and method of administration

Treatment should be initiated and supervised by specialist medical practitioners experienced in the diagnosis and management of SMA.

#### Dose

The recommended dosage is 12 mg (5 mL) per administration. Initiate SPINRAZA treatment as early as possible after diagnosis with 4 loading doses on Days 0, 14, 28, and 63. A maintenance dose should be administered once every 4 months thereafter. (See *Special dosage instructions for intrathecal administration*).

#### Dose delay

If a loading or a maintenance dose is delayed or missed SPINRAZA should be administered according to the schedule in Table 1 below.

**Table 1: Dosing administration of delayed or missed dose**

Delayed or missed dose	Timing of Dosing Administration
<b>Loading dose</b>	
<ul style="list-style-type: none"><li>Administer the delayed or missed loading dose as soon as possible with at least 14 days between doses; continue with subsequent doses on the prescribed intervals from the last dose.</li></ul>	
e.g. if the third loading dose is administered 30 days late at Day 58 (instead of the original	

schedule at Day 28), then the fourth loading dose should be administered 35 days later at Day 93 (instead of the original schedule at Day 63) with a maintenance dose 4 months thereafter.

<b>Maintenance dose</b>	<b>Timing of Dosing Administration</b>
>4 to <8 months from last dose	<ul style="list-style-type: none"> <li>• Administer the delayed maintenance dose as soon as possible; then</li> <li>• The next maintenance dose per the original scheduled date, as long as these two doses are administered at least 14 days apart; then</li> <li>• Maintenance dose 4 months after the last dose and repeat every 4 months.</li> </ul>
≥8 to <16 months from last dose	<ul style="list-style-type: none"> <li>• Administer the missed dose as soon as possible and then the next dose 14 days later; then</li> <li>• Maintenance dose 4 months after the last dose and repeat every 4 months.</li> </ul>
≥16 to <40 months from last dose	<ul style="list-style-type: none"> <li>• Administer the missed dose as soon as possible and then the next dose 14 days later, followed by a third dose 14 days later; then</li> <li>• Maintenance dose 4 months after the last dose and repeat every 4 months.</li> </ul>
≥ 40 months from last dose	<ul style="list-style-type: none"> <li>• Administer the dosing regimen on the prescribed intervals (Days 0, 14, 28 and 63 after treatment is re-started); then the maintenance dose 4 months after the last dose and repeat every 4 months.</li> </ul>

## Special populations

### **Adults**

There are limited clinical data in patients over the age of 18 years. There is real world evidence data from post-marketing experience in adult SMA patients (see Sections 4.8 Undesirable effects and 5.1 Pharmacodynamic properties).

### **Paediatric population**

SPINRAZA has been studied in patients ranging from newborn to 17 years (See Section 5.1).

### **Elderly**

There are no data in patients over the age of 65.

### **Renal impairment**

SPINRAZA has not been studied in patients with renal impairment.

### **Hepatic impairment**

SPINRAZA has not been studied in patients with hepatic impairment. SPINRAZA is not metabolised via the cytochrome P450 enzyme system in the liver; therefore dosage adjustment is unlikely to be required in patients with hepatic impairment (See Sections 4.5 and 5.2).

### Method of administration

Treatment should be administered by health care professionals experienced in performing lumbar punctures.

SPINRAZA is for intrathecal use by lumbar puncture.

### ***Instructions for preparation of the injection***

1. The SPINRAZA vial should be inspected for particles prior to preparation. If particles are observed and/or the liquid in the vial is not clear and colourless, the vial must not be used.
2. Aseptic technique should be used when preparing SPINRAZA solution for intrathecal administration.
3. The vial should be taken out of the refrigerator and allowed to warm to room temperature (25°C) without using external heat sources, prior to administration.
4. If the vial remains unopened and the solution is not used, it should be returned back to the refrigerator (2-8°C).
5. Just prior to administration, insert the syringe needle into the vial through the centre of the over-seal to remove the appropriate volume (see *Dose and Dose delay*). SPINRAZA must not be diluted.
6. Once drawn in to the syringe, if the solution is not used within 6 hours, it must be discarded.
7. Any unused product or waste material must be disposed of in accordance with local requirements.

### ***Special Dosage Instructions for intrathecal administration***

1. The solution must be visually inspected prior to administration. Only clear and colourless solutions, free from particles, should be administered. The use of external filters is not required.
2. Aseptic technique must be used when administering SPINRAZA.
3. Sedation may be required to administer SPINRAZA, as indicated by the clinical condition of the patient.
4. Ultrasound (or other imaging techniques) may be considered to guide intrathecal administration of SPINRAZA, particularly in younger patients.
5. It is recommended that the volume of cerebrospinal fluid equivalent to the volume of SPINRAZA to be injected is removed prior to administration of SPINRAZA.
6. SPINRAZA is administered as an intrathecal bolus injection over 1 to 3 minutes, using a spinal anaesthesia needle. The injection must not be administered in areas of the skin where there are signs of infection or inflammation.
7. Any unused contents of the vial should be discarded.

SPINRAZA is for single use in one patient only. Discard any residue.

## **4.3 Contraindications**

SPINRAZA is contraindicated in patients who have a history of hypersensitivity reactions, to the active ingredient or to any of the excipients listed in section 6.1.

## **4.4 Special warnings and precautions for use**

### Thrombocytopenia and coagulation abnormalities

Thrombocytopenia and coagulation abnormalities, including acute severe thrombocytopenia, have been observed after administration of other subcutaneously or intravenously administered antisense oligonucleotides. If clinically indicated, platelet and coagulation laboratory testing is recommended prior to administration of SPINRAZA.

### Renal toxicity

Renal toxicity has been observed after administration of other subcutaneously and intravenously administered antisense oligonucleotides.

In a combined analysis of the sham-controlled studies for patients with infantile-onset and later-onset SMA, 71 of 123 (58%) of SPINRAZA-treated patients had elevated urine protein, compared to 22 of 65 (34%) sham-controlled patients.

If clinically indicated, urine protein testing (preferably using a first morning urine specimen) is recommended. For persistent elevated urinary protein, further evaluation should be considered.

### Hydrocephalus

There have been reports of communicating hydrocephalus not related to meningitis or bleeding in patients treated with nusinersen in the post-market setting. Some patients were implanted with a ventriculo-peritoneal shunt. In patients with decreased consciousness, an evaluation for hydrocephalus should be considered. The benefits and risks of nusinersen treatment in patients with a ventriculo-peritoneal shunt are unknown at present and the maintenance of treatment needs to be carefully considered.

### Type 0 or IV SMA

Patients most likely to develop type 0 or IV SMA have not been included in the clinical development program for SPINRAZA. The decision to treat should be based on individualised expert evaluation of the expected benefits of treatment for that individual, balanced against the potential risk of treatment with nusinersen. The full benefits and risks are unknown among patients diagnosed with type 0 or IV SMA.

## **4.5 Interaction with other medicines and other forms of interaction**

No clinical studies of interactions with other medicines have been performed.

Nusinersen is metabolised via nucleases and not by the cytochrome P450 (CYP450) system.

*In vitro* studies indicated that nusinersen is not an inducer or inhibitor of CYP450 mediated metabolism.

*In vitro* studies indicate that the likelihood for interactions with nusinersen due to competition for plasma protein binding, or competition with or inhibition of transporters is low.

## **4.6 Fertility, pregnancy and lactation**

### Pregnancy

Australian categorisation system for prescribing medicines in pregnancy: Category B1

Data from nonclinical studies do not suggest that nusinersen would be associated with effects on embryofetal development. Administration of nusinersen via subcutaneous injection to mice and rabbits at doses up to 25 mg/kg every other day (87.5 mg/kg/week) did not produce any adverse effects on embryofetal development. Using liver concentration as a measure of systemic exposure, the estimated nusinersen concentration in the liver at 25 mg/kg every other day (87.5 mg/kg/week) provides an approximately  $\geq 8.4$ -fold margin over the liver nusinersen concentration in humans at the maximum recommended clinical dose of 12 mg.

The effects of nusinersen on labour and delivery in humans are unknown.

## Breast-feeding

There are no data on the presence of nusinersen in human milk, the effects on the breastfed infant or the effects of the drug on milk production.

## Fertility

Data from nonclinical studies do not suggest that nusinersen would be associated with effects on male or female fertility. Administration of nusinersen via subcutaneous injection to male and female mice at doses of up to 25 mg/kg every other day (87.5 mg/kg/week) had no effects on fertility.

There are no data on the effects of nusinersen on human fertility.

## **4.7 Effects on ability to drive and use machines**

No studies on the effects on the ability to drive or use machines during treatment with SPINRAZA have been performed.

## **4.8 Undesirable effects**

### Summary of the safety profile

The safety of SPINRAZA in infants and children with SMA was assessed in 3 randomised, double-blind, sham-controlled studies two of which were phase 3 (Study CS3B and Study CS4) and one phase 2 (Study SM202, in an open-label phase 2 study in symptomatic infants (Study CS3A), an open-label study in pre-symptomatic infants genetically diagnosed with SMA (Study CS5) and in patients aged 2 to 15 years (at first dose) in an integrated analysis of 4 open-label studies (Studies CS2, CS12, CS1 and CS10). Study CS11 enrolled infantile- and later-onset patients including those who complete studies CS3B, CS4 and CS12. A total of 352 SMA patients were treated with SPINRAZA and total time on study ranged from 6 to 3940 days (median 2445 days).

In Study CS3B, 121 patients were dosed, of whom 80 patients received SPINRAZA (median exposure 280 days) and 41 patients received sham-control (median exposure 187 days).

In Study CS4, 126 patients were dosed, of whom 84 patients received SPINRAZA (median exposure 451 days) and 42 patients received sham-control (median exposure 450 days).

### Tabulated summary of adverse reactions

Adverse events reported at an incidence at least 5% higher in patients treated with SPINRAZA compared to sham-control in Studies CS3B and CS4 are summarised in Tables 2 and 3, respectively and across studies in Table 4. Events reported across open-label studies CS3A, CS2, CS12, CS5, CS1, CS10, CS11 and the double-blind study SM202 were consistent with those observed in Studies CS3B and CS4. No serious adverse events were considered related to study drug. The majority of adverse events reported in clinical trials were considered related to SMA disease or related to intrathecal administration procedure.

The adverse events are presented as MedDRA preferred terms and are listed by system organ class and frequency using the following convention: Very Common ( $\geq 1/10$ ); Common ( $\geq 1/100 - <1/10$ ); Uncommon ( $\geq 1/1,000 - <1/100$ ); Rare ( $\geq 1/10,000 - <1/1,000$ ); Very Rare ( $<1/10,000$ ).

Within each frequency grouping, adverse events are presented in order of decreasing

seriousness.

**Table 2: Adverse events reported in Study CS3B with an incidence at least 5% and is higher in patients treated with SPINRAZA than Sham-Control**

MedDRA preferred term	SPINRAZA n=80	Sham-control n=41	SPINRAZA Frequency Category <sup>^</sup>	
			Very Common (≥ 1/10)	Common (≥ 1/100 - <1/10)
Upper respiratory tract infection	24 (30%)	9 (22%)	Very Common	
Pneumonia	23 (29%)	7 (17%)	Very Common	
Nasopharyngitis	15 (19%)	4 (10%)	Very Common	
Respiratory tract infection	9 (11%)	2 (5%)	Very Common	
Bronchiolitis	8 (10%)	3 (7%)	Very Common	
Viral infection	8 (10%)	3 (7%)	Very Common	
Oral candidiasis	7 (9%)	3 (7%)		Common
Pneumonia viral	7 (9%)	2 (5%)		Common
Urinary tract infection	7 (9%)	0 (0%)		Common
Bronchitis	6 (8%)	1 (2%)		Common
Bronchitis viral	5 (6%)	0 (0%)		Common
Ear infection	5 (6%)	1 (2%)		Common
Influenza	5 (6%)	0 (0%)		Common
Hypoxia	7 (9%)	2 (5%)		Common
Rhinorrhoea	6 (8%)	3 (7%)		Common
Upper respiratory tract congestion	6 (8%)	1 (2%)		Common
Constipation	28 (35%)	9 (22%)	Very Common	
Teething	14 (18%)	3 (7%)	Very Common	
Salivary hypersecretion	6 (8%)	2 (5%)		Common
Rash	9 (11%)	4 (10%)	Very Common	
Weight gain poor	5 (6%)	2 (5%)		Common

<sup>^</sup> Frequency category based upon SPINRAZA treated adverse event.

\*Adverse events which are verbally communicated, such as those which commonly occur in the setting of lumbar puncture procedure, could not be assessed due to the infantile patient population.

**Table 3: Adverse events reported in CS4 with an incidence at least 5% and is higher in patients treated with SPINRAZA than Sham-Control**

MedDRA preferred term	SPINRAZA n=84	Sham-control n=42	SPINRAZA Frequency Category <sup>^</sup>	
			Very Common (≥ 1/10)	Common (≥ 1/100 - <1/10)
Influenza	8 (10%)	3 (7%)	Very Common	
Conjunctivitis	6 (7%)	2 (5%)		Common
Pyrexia	36 (43%)	15 (36%)	Very Common	
Headache*	24 (29%)	3 (7%)	Very Common	
Vomiting*	24 (29%)	5 (12%)	Very Common	
Diarrhoea	8 (10%)	3 (7%)		Common
Cough	21 (25%)	9 (21%)	Very Common	
Epistaxis	6 (7%)	0		Common
Upper respiratory tract congestion	5 (6%)	2 (5%)		Common
Back pain*	21 (25%)	0	Very Common	

<sup>^</sup> Frequency category based upon SPINRAZA treated adverse event.

\*Adverse events considered related to the lumbar puncture procedure. These events can be considered manifestations of post-lumbar puncture syndrome.

**Table 4: Incidence of possibly drug-related adverse events across all studies in patients treated with SPINRAZA<sup>^</sup>#.**

MedDRA preferred term	Pre-symptomatic infants (CS5) (n=20)	Patients with infantile onset SMA		Patients with later onset SMA	
		CS3A (n=20)	CS3B (n=80)	CS4 (n=84)	CS2-12 (n=56)
Headache*	0	0	0	8 (10%)	1 (2%)
Hyperreflexia	1 (5%)	0	1 (1%)	0	0
Post lumbar puncture syndrome*	0	0	0	2 (2%)	2 (4%)
Tachycardia	1 (5%)	0	1 (1%)	1 (1%)	1 (2%)
Vomiting	0	1 (5%)	0	2 (2%)	0
Pyrexia	1 (5%)	0	2 (3%)	6 (7%)	0
Back pain*	0	0	0	7 (8%)	0
Muscular weakness	1 (5%)	0	0	1 (1%)	0

\*Adverse events which are verbally communicated, such as those which commonly occur in the setting of lumbar puncture procedure, could not be assessed due to the infantile patient population and could only be assessed in the later onset patient population.

<sup>^</sup>Events were determined as possibly drug-related by the investigator.

<sup>#</sup>Events listed are those which occurred in 2 patients across all studies.

### **Use in adults from post-marketing setting**

Safety data in the adult population from use in the post-marketing setting are consistent with the known safety profile of nusinersen and with co-morbidities associated with the underlying disease of SMA. No controlled data are available. (see Section 5.1 Pharmacodynamic properties).

### **Description of selected adverse reactions**

#### ***Lumbar-puncture-related events***

Adverse events associated with the administration of SPINRAZA by lumbar puncture, such as headache, back pain, vomiting, procedure-related haematoma and post lumbar puncture syndrome, have been observed. The incidence and severity of these events were consistent with events expected to occur with lumbar puncture. No serious complications of lumbar puncture, such as serious infections, have been observed in clinical studies.

#### ***Post marketing experience***

Adverse reactions associated with SPINRAZA have been observed in the post-marketing setting. Serious adverse reactions include aseptic meningitis, serious infections in the context of lumbar puncture, such as meningitis, and arachnoiditis. Repeated lumbar puncture is a risk factor for arachnoiditis and is a confounder.

Serious adverse events of hydrocephalus have also been observed in the post marketing setting (see Section 4.4 Special warnings and precautions for use).

Other nonserious adverse reactions reported in the post marketing setting include: pyrexia and hypersensitivity (eg, rash, elevated eosinophils, grade 1 angioedema or serum sickness).

These reactions are reported voluntarily in a population of an uncertain size, and therefore it is not always possible to estimate their frequency.

### **Reporting of suspected adverse reactions**

Reporting suspected adverse reactions after authorisation of the medicine is important. It

allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions <https://pophealth.my.site.com/carmreportnz/s/>

## 4.9 Overdose

No cases of overdose associated with adverse reactions were reported in clinical studies. In case of overdose with SPINRAZA the patient should be advised to seek medical attention if they experience any signs or symptoms of adverse reactions.


For risk assessment and advice on the management of overdose please contact the National Poisons Centre on 0800 POISON (0800 764766).

## 5. PHARMACOLOGICAL PROPERTIES

### 5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Musculo-skeletal system, ATC code: M09AX07

Nusinersen is a fully modified 2'-O-2 methoxyethyl antisense oligonucleotide designed to bind to a specific sequence in the intron downstream of Exon 7 of the SMN2 transcript.



CAS registry number (nusinersen): 1258984-36-9

C<sub>234</sub>H<sub>340</sub>N<sub>61</sub>O<sub>128</sub>P<sub>17</sub>S<sub>17</sub> (nusinersen) MW 7127.1 g/mol

C<sub>234</sub>H<sub>323</sub>N<sub>61</sub>O<sub>128</sub>P<sub>17</sub>S<sub>17</sub>Na<sub>17</sub> (nusinersen heptadecasodium) MW 7501.0 g/mol

Chemical name:

*all-P-ambo-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioadenylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioguanylyl-*

(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-*P*-thiocytidylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-*P*-thiouridylyl-(3'→5')-2'-O-(2-methoxyethyl)-*P*-thioguanilyl-(3'→5')-2'-O-(2-methoxyethyl)guanosine

The pKa of the dinucleoside phosphate diester is approximately 2. The bases have acidic and basic pKas ranging from approximately 3.5 to 10 and the 5' and 3'-hydroxy groups have pKas of approximately 16 and 12, respectively. The API is a white to yellow amorphous, hygroscopic solid.

### Mechanism of action

SPINRAZA is an antisense oligonucleotide (ASO) specifically designed to treat Spinal Muscular Atrophy (SMA), an autosomal recessive progressive neuromuscular disease, due to mutations in the chromosome 5q. These mutations lead to loss of function of the survival motor neuron 1 (SMN1) gene, resulting in deficiency of SMN protein. The SMN2 gene also produces SMN protein but at low levels.

SMA is a clinical spectrum of disease, with age of onset and disease severity associated to the number of SMN2 gene copies present; fewer SMN2 gene copies are associated with earlier age of onset and increased severity of symptoms.

Nusinersen (contained in SPINRAZA) increases the proportion of exon 7 inclusion in SMN2 messenger ribonucleic acid (mRNA) transcripts by binding to an intronic splice silencing site (ISS-N1) found in intron 7 of the SMN2 pre-messenger ribonucleic acid (pre-mRNA). By binding, the ASO displaces splicing factors, which normally suppress splicing. Displacement of these factors leads to retention of exon 7 in the SMN2 mRNA. Once SMN2 mRNA is produced, it can be translated into the functional full length SMN protein.

### Pharmacodynamic effects

The pharmacodynamic effects are consistent with the biological effects of nusinersen.

Autopsy samples from treated infants had higher levels of SMN2 messenger ribonucleic acid (mRNA) containing exon 7 in the thoracic spinal cord compared to untreated SMA infants.

### Immunogenicity

The immunogenic response to SPINRAZA was evaluated in 342 patients with post-baseline plasma samples for antidrug antibodies (ADAs). Overall, 36 SPINRAZA-treated patients (11%) developed treatment-emergent ADAs, of which 14 (4%) were transient and 22 (6%) were persistent. No discernible effects of ADAs on efficacy or safety have been observed as measured by incidence of AEs including hypersensitivity reaction, anaphylactic reaction, and angioedema.

### Clinical efficacy and safety

The efficacy of SPINRAZA was demonstrated in 7 clinical trials in symptomatic patients (Studies CS3B, CS3A, CS4, CS2, CS12, SM202 and CS11), who ranged in age from 30 days to 15 years at the time of first dose, and one clinical trial in pre-symptomatic patients (Study CS5), who ranged in age from 3 days to 42 days at the time of first dose. Efficacy results from these studies demonstrate that treatment with SPINRAZA provides benefit across disease phenotypes and support the initiation of treatment as soon as possible following diagnosis (Figures 6, 7, 8 and 9). SPINRAZA has only been studied in patients with 5q SMA.

Motor function measures used in clinical studies:

- Hammersmith Infant Neurological Examination (HINE) Section 2: a measure of the achievement of motor milestones comprised of 8 milestone categories (head control,

sitting, grasping, ability to kick in supine position, rolling, crawling, standing and walking) with 3 to 5 progressively more difficult items for each milestone category.

- WHO motor milestones: a set of 6 major motor milestones (sitting without support, standing with assistance, hands and knees crawling, walking with assistance, standing alone, walking alone) that are expected to be attained by 24 months of age in healthy children.
- Children's Hospital of Philadelphia Infant Test for Neuromuscular Disease (CHOP INTEND): a 64-point motor assessment that captures neck, trunk, proximal, and distal limb strength in 14 elicited and 2 observational items, designed to evaluate muscle strength and function in infants with SMA.
- Hammersmith Functional Motor Scale – Expanded (HFMSE): a measure to assess motor function in children with limited ambulation, comprising of 33 scored activities that give objective information on motor ability and clinical progression.
- Upper Limb Module (ULM): designed to assess upper limb function in nonambulatory patients, consisting of 9 upper limb performance items reflective of activities of daily living. Higher scores indicate greater functional abilities.
- Revised Upper Limb Module (RULM): designed to assess upper limb function in patients with SMA, consisting of 20 items for a maximum total score of 37,
- Six-Minute Walk Test (6 MWT): an evaluation of the distance a person can walk quickly in 6 minutes.
- Compound Muscle Action Potential (CMAP): an electrophysiological measure of motor neuron health for tracking disease progression in neuromuscular disorders, such as SMA.

## **Symptomatic Patients**

### Patients with Infantile-onset SMA

#### *Study CS3B (ENDEAR)*

Study CS3B was a phase 3, randomised, double-blind, sham-procedure controlled study conducted in 121 symptomatic infants  $\leq 7$  months of age, diagnosed with SMA (symptom onset before 6 months of age). Patients were randomised 2:1 to either SPINRAZA or sham-control, with a length of treatment ranging from 6 to 442 days (median 258). SPINRAZA-treated patients received a 12 mg scaled equivalent dose based on CSF volume scaling on study days 1, 15, 29, 64, 183 and 302. The median age of onset of clinical signs and symptoms of SMA was 6.5 weeks (range 2-18) and 8 weeks (range 1-20) for SPINRAZA-treated versus sham-control patients respectively, with 99% of patients having 2 copies of the SMN2 gene. Patients in this study were deemed most likely to develop Type I SMA. At baseline, the mean total motor milestone score was 1.37 (range 0-6), the median CHOP INTEND score was 28 (range 8-50.5), and the median CMAP amplitudes were 0.20 (range 0.00-0.87) and 0.30 (range 0.00-1.50) for the ulnar nerve and peroneal nerves, respectively. The median age when patients received their first dose was 164.5 days (range 52-242) for treated patients, and 205 days (range 30-262) for sham-control.

Baseline disease characteristics were largely similar in the SPINRAZA treated patients and sham-control patients except that SPINRAZA treated patients at baseline had a higher percentage compared to sham-control patients of paradoxical breathing (89% vs 66%), pneumonia or respiratory symptoms (35% vs 22%), swallowing or feeding difficulties (51% vs 29%) and requirement for respiratory support (26% vs 15%).

A planned interim analysis was conducted based on patients with the opportunity to reach a 6 month evaluation. The primary endpoint assessed at the interim analysis was the proportion of responders: patients achieving a pre-defined level of improvement in motor milestones (HINE Section 2).

At the final analysis, time to death or permanent ventilation ( $\geq 16$  hours ventilation/day continuously for  $> 21$  days in the absence of an acute reversible event or tracheostomy) was assessed as the primary endpoint. Statistically significant effects on event-free survival, overall survival, the proportion of patients achieving the definition of a motor milestone responder, and the percentage of patients with at least a 4-point improvement from baseline in CHOP-INTEND score were observed in patients in the SPINRAZA group compared to those in the sham-control group (Table 5, Figures 1 and 2).

In the efficacy set, 18 (25%) patients in the SPINRAZA group and 12 (32%) patients in the sham-control group required permanent ventilation. Of these patients, 6 (33%) in the SPINRAZA group and 0 (0%) in the sham-control group met the protocol-defined criteria for a motor-milestone responder.

**Table 5: Primary and secondary endpoints at final analysis – Study CS3B**

<b>Efficacy Parameter</b>	<b>SPINRAZA-treated Patients</b>	<b>Sham-control Patients</b>
<b>Survival</b>		
<b>Event-free survival<sup>2,3</sup></b>		
Number of patients who died or received permanent ventilation	31 (39%)	28 (68%)
Hazard ratio (95% CI)	0.53 (0.32 -0.89)	
p-value <sup>4</sup>	p = 0.0046	
<b>Overall survival<sup>2</sup></b>		
Number of patients who died	13 (16%)	16 (39%)
Hazard Ratio (95% CI)	0.37 (0.18 – 0.77)	
p-value <sup>4</sup>	p=0.0041	
<b>Motor function</b>		
<b>Motor milestones<sup>5</sup></b>		
Proportion achieving pre-defined motor milestone responder criteria (HINE section 2) <sup>6,7</sup>	37 (51%) <sup>1</sup> P<0.0001	0 (0%)
Proportion at Day 183 <sup>8</sup>	41%	5%
Proportion at Day 302 <sup>8</sup>	45%	0%
Proportion at Day 394 <sup>8</sup>	54%	0%
Proportion with improvement in total motor milestone score	49 (67%)	5 (14%)
Proportion with worsening in total motor milestone score	1 (1%)	8 (22%)
<b>CHOP-INTEND<sup>5</sup></b>		
Proportion achieving a 4-point improvement	52 (71%) P<0.0001	1 (3%)
Proportion achieving a 4-point worsening	2 (3%)	17 (46%)
Proportion with any improvement	53 (73%)	1 (3%)
Proportion with any worsening	5 (7%)	18 (49%)

<sup>1</sup>CS3B was stopped following positive statistical analysis on the primary endpoint at interim analysis (statistically significantly greater percentage of patients achieved the definition of a motor milestone responder in the SPINRAZA group (41%) compared to the sham-control group (0%), p<0.0001).

<sup>2</sup>At the final analysis, event-free survival and overall survival were assessed using the Intent to Treat population (ITT SPINRAZA n=80; Sham-control n=41).

<sup>3</sup>Median time to death or permanent ventilation was not reached in SPINRAZA group, and was 22.6 weeks in the sham-control group

<sup>4</sup>Based on log-rank test stratified by disease duration

<sup>5</sup>At the final analysis, CHOP-INTEND and motor milestone analyses were conducted using the Efficacy Set (SPINRAZA n=73; Sham-control n=37).


<sup>6</sup>Assessed at the later of Day 183, Day 302, and Day 394 Study Visit

<sup>7</sup>According to HINE section 2: ≥ 2-point increase [or maximal score] in ability to kick, OR ≥1 point

increase in the motor milestones of head control, rolling, sitting, crawling, standing or walking, AND improvement in more categories of motor milestones than worsening), defined as a responder for this primary analysis.

<sup>8</sup>The proportion of motor milestones responders at Day 183, Day 302, and Day 394 are based on evaluable sets at those visits


**Figure 1: Overall Survival (ITT) – Study CS3B**



SOURCE: isis396443/iss/cds-update-nov2018/f-time-overall-cs3b-bw.sas

DATE: 03DEC2018

**Figure 2: Change in Total Motor Milestone Score from Baseline to Later of Day 183, Day 302, and Day 394 Study Visit (Efficacy Set) – Study CS3B**



Note 1: Shortest bars at 0 line indicate 0 value.

Note 2: Out of the 110 subjects in the efficacy set, 29 died (13 (18%) for nusinersen and 16 (43%) for Control) and 3 withdrew for reason other than death (2 (3%) for nusinersen and 1 (3%) for Control) and were therefore not included in this analysis of the ES.

SOURCE: isis396443/iss/cds-update-nov2018/f-motor-milestone-chg-wf-bw-aus.sas

DATE: 06MAR2019

Of the 121 (80 SPINRAZA and 41 sham) patients in study CS3B, 89 patients (65 SPINRAZA and 24 post-sham) enrolled in the ongoing open-label extension study (study CS11). In patients randomised to SPINRAZA in study CS3B and including the extension of SPINRAZA treatment in Study CS11, patients received the medication for 6 to 3043 days (median 2443 days). In patients randomised to sham in Study CS3B and initiating SPINRAZA in Study CS11, patients received the medication for 65 to 2520 days (median 2090 days). Improvements in motor function were observed for patients continuing SPINRAZA from study CS3B and patients who initiated SPINRAZA in study CS11 (Figures 8 and 9). The greatest observed benefit was in those with earlier treatment initiation. The majority of patients were alive at their last visit after initiating treatment with SPINRAZA in either Study CS3B or study CS11.

Patients initiating SPINRAZA in study CS3B were of median age of 5.4 months (range 1.7 to 14.9 months). From SPINRAZA initiation and including extension of treatment in study CS11, the median time to death or permanent ventilation was 1.4 years. At the end of study CS11, 60/81 (74%) patients were alive and 41/81 (51%) were alive and had not met the Study CS11 definition of permanent ventilation. Mean HINE-2 total motor milestone score increased by 5.3 (SD 4.6; n=53) and CHOP INTEND increased by 18.4 (SD 14.7, n=38) points from initiation of SPINRAZA to follow up visit day 394 and 2198 respectively.

Patients randomised to sham in Study CS3B and initiating SPINRAZA in Study CS11 were of a median age of 17.8 months (range 10.1 – 23.0 months). Prior to treatment with SPINRAZA 12/24 patients (50%) had met the Study CS11 definition of permanent ventilation. The median time to death or permanent ventilation was 2.76 years after initiation of SPINRAZA in study CS11. At the end of Study CS11, 19/24 (79%) patients were alive and 6/12 (50%) were alive without permanent ventilation. Improvement in mean total motor milestone score of 1.4 (SD 1.8; n=12) and CHOP INTEND score of 11.5 (SD 12.2, n=10) were observed from Study CS11

baseline to follow up visit day 394 and 2198 respectively.

### *Study CS3A*

Study CS3A was an open-label phase 2 study in symptomatic patients diagnosed with SMA. Median age of onset of clinical signs and symptoms was 56 days (range 21 to 154 days) and patients had either 2 SMN2 gene copies (n=17) or 3 SMN2 gene copies (n=2) (SMN2 gene copy number unknown for 1 patient). Patients in this study were deemed most likely to develop Type I SMA. Patients were randomised to receive either a 6 mg or 12 mg scaled equivalent dose of SPINRAZA based on CSF volume during the loading dose phase on days 1, 15 and 85. During the maintenance phase all patients received a 12 mg scaled dose on days 253, 379, 505, 631, 757, 883, 1009, 1135 and 1261. Median age at first dose was 162 days (range 37-223). At screening, the median number of motor milestones (HINE section 2) achieved was 2 (range 1 to 12), median CHOP-INTEND total score was 27 (range 17 to 64), median baseline ulnar CMAP amplitude was 0.235 mV (range 0.00 to 3.20 mV) and baseline peroneal CMAP amplitude was 0.345 mV (range 0.00 to 2.70 mV). The patients in the study had a median time on study of 1101 days (range 62 – 1429 days).

As of the study closure date, 15 of 20 patients (75%) were alive and 5 patients had died [aged 5.13 to 36.28 months]. 11 (55%) were alive and free of permanent ventilation (4 patients were on permanent ventilation aged 6.28 to 39.97 months) (See Figure 4). Of the 15 patients alive all were at least 14 months of age (median 43.5 months, range 14.1 to 54 months), with 6 at > 45 months and 2 at > 50 months of age.

The primary endpoint was the proportion of patients who improved in one or more categories in motor milestones (HINE Section 2). (according to HINE section 2:  $\geq 2$  point increase [or maximal score] in ability to kick or voluntary grasp OR  $\geq 1$  point increase in the motor milestones of head control, rolling, sitting, crawling, standing or walking). Twelve out of 20 patients (60%) had met the primary endpoint, with a sustained improvement in mean motor milestone achievement over time (See Figures 8 and 9). In contrast to the natural history of SMA where there is a failure to achieve motor milestones after symptom onset, 8 of 20 patients (40%) developed the ability to sit independently, 4 of 20 patients (20%) gained the ability to stand with support or independently, 2 of 20 patients (10%) gained the ability to walk with support or independently.

A sustained improvement in mean CHOP-INTEND score was observed from baseline to day 1072 (mean change 21.30). Overall, 11 out of 20 patients (55%) met the endpoint of an increase in total CHOP INTEND score of  $\geq 4$  points as of their last study visit prior to data cut-off.

### *Patients with later-onset SMA*

#### *Study CS4 (CHERISH)*


Study CS4 was a phase 3, randomised, double-blind, sham-procedure controlled study in 126 symptomatic children with later-onset SMA (symptom onset after 6 months of age). Patients were randomised 2:1 to either SPINRAZA or sham-control, with a length of treatment ranging from 324 to 482 days (median 450). SPINRAZA-treated patients received a 12 mg (5 mL) dose on study days 1, 29, 85 and 274.

The median age at screening was 3 years (range 2-9), and the median age of onset of clinical signs and symptoms of SMA was 11 months (range 6-20). The majority of patients (88%) have 3 copies of the SMN2 gene (8% have 2 copies, 2% have 4 copies, and 2% have an unknown copy number). At baseline, patients had a mean HFMSE score of 21.6, a mean RULM of 19.1, all had achieved independent sitting, and no patients had achieved independent walking. Patients in this study were deemed most likely to develop Type II or III SMA. Baseline disease characteristics were generally similar except for an imbalance in the proportion of patients who

had ever achieved the ability to stand without support (13% of patients in the SPINRAZA group and 29% in sham-control) or walk with support (24% of patients in the SPINRAZA group and 33% in sham-control).

At the final analysis, a statistically significant improvement in HFMSE score from baseline to Month 15 was seen in the SPINRAZA group compared to the sham-control group (Table 6, Figure 3). The analysis was conducted in the ITT population (SPINRAZA: n=84; sham-control: n=42), and post-baseline HFMSE data for patients without a Month 15 visit were imputed using the multiple imputation method. An analysis of the subset of patients in the ITT population who had observed values at Month 15 demonstrated consistent, statistically significant results. Of those with observed values at Month 15, a higher proportion of SPINRAZA treated patients had improvement (73% vs 41%, respectively) and a lower proportion had worsening (23% vs 44%, respectively) in total HFMSE score compared to sham-control (Figure 4). All secondary endpoints including functional measures and WHO motor milestone achievement were formally statistically tested and are described in Table 6 and illustrated in Figure 5. Initiation of treatment sooner after symptom onset resulted in earlier and greater improvement in motor function than those with delayed treatment initiation; however, both groups experienced benefit compared to sham-control.

**Figure 3: Mean change from baseline in HFMSE score over time at final analysis (ITT) – Study CS4<sup>1,2,3</sup>**



SOURCE: ISIS396443/ISS/CDS-UPDATE-NOV2018/F-HMCHG-CS4-BW-AUS.SAS

DATE: 06MAR2019

<sup>1</sup>Data for patients without a Month 15 visit were imputed using the multiple imputation method

<sup>2</sup>Error bars denote +/- standard error

<sup>3</sup>This graph was a pre-specified exploratory analysis of HFSME scores over time

**Table 6: Primary and secondary endpoints at final analysis – Study CS4**

	<b>SPINRAZA-treated Patients</b>	<b>Sham-control Patients</b>
<b>HFMSE score</b>		
Change from baseline in total HFMSE score at 15 months <sup>1,2,3,4</sup>	3.9 (95% CI: 3.0, 4.9) p=0.0000001	-1.0 (95% CI: -2.5, 0.5)
Proportion of patients who achieved at least a 3-point improvement from baseline to month 15 <sup>2</sup>	56.8% (95% CI: 45.6, 68.1) p=0.0006 <sup>5</sup>	26.3% (95% CI: 12.4, 40.2)
<b>RULM</b>		
Mean change from baseline to month 15 in total RULM score <sup>2,3,4</sup>	4.2 (95% CI: 3.4, 5.0)	0.5 (95% CI: -0.6, 1.6)
<b>WHO motor milestones</b>		
Proportion of patients who achieved new motor milestones at 15 months <sup>5</sup>	19.7% (95% CI: 10.9, 31.3) p=0.0811	5.9% (95% CI: 0.7, 19.7)
Mean number of new motor milestones attained <sup>3,4,5</sup>	0.2 (range -1 to 2, 95% CI: 0.1, 0.3)	-0.2 (range -1 to 1, 95% CI: -0.4, 0.0) <sup>3</sup>

<sup>1</sup>CS4 was stopped following positive statistical analysis on the primary endpoint at interim analysis (statistically significant improvement from baseline HFMSE score was observed in SPINRAZA treated patients compared to the sham-control patients (SPINRAZA vs. sham-control: 4.0 vs. -1.9; p=0.0000002)).

<sup>2</sup>Assessed using the Intent to Treat population (SPINRAZA n=84; Sham-control n=42); data for patients without a Month 15 visit were imputed using the multiple imputation method.


<sup>3</sup>Least squares mean.

<sup>4</sup>Negative value indicates worsening, positive value indicates improvement.

<sup>5</sup>Assessed using the Month 15 Efficacy Set (SPINRAZA n=66; Sham control n=34); analyses are based on imputed data when there are missing data.

<sup>6</sup>Based on logistic regression with treatment effect and adjustment for each patient's age at screening and HFMSE score at baseline.

**Figure 4: Waterfall plot for change from baseline to Month 15 on HFMSE at final analysis (ITT Set)\***




NOTE: This figure is based upon subjects with an observed value. Shortest bars at 0 line indicate 0 value.

SOURCE: isis396443/iss/cds-update-nov2018/f-hfmse-wf-m15-bw-aus.sas

DATE: 06MAR2019

\*26 patients are not included in this presentation as they did not attend Month 15. This was because the study was stopped by the sponsor to allow them the opportunity to rollover into the open label extension study.

**Figure 5: Waterfall plot for change from baseline to Month 15 on RULM at final analysis (ITT Set)**



NOTE: This figure is based upon subjects with an observed value. Shortest bars at 0 line indicate 0 value.

SOURCE: isis396443/iss/cds-update-nov2018/f-ult-wf-m15-bw-aus.sas

DATE: 06MAR2019

125 patients (83 SPINRAZA and 42 sham) enrolled in Study CS4 and continued follow-up in the open-label extension (Study CS11). In patients randomised to SPINRAZA in Study CS4 and including the extension of treatment with SPINRAZA in Study CS11, patients received the medication for a median time of 7.2 years (range 1.3 to 8.4 years). In patients randomised to sham in Study CS4 and initiating SPINRAZA in Study CS11, patients received the medication for a median time of 5.8 years (range 2.7 to 6.7 years). Many of the patients treated with SPINRAZA experienced improvement in motor function in at least one of the two motor function tests measured up to follow up visit day 2070, with the greatest benefit observed in those who initiated treatment with SPINRAZA at the youngest age.

Patients initiating SPINRAZA in Study CS4 were of median age 4.1 years (range 2.1-9.2 years). From SPINRAZA initiation and including extension of treatment in Study CS11, HFMSE change was a mean increase of 1.3 (SD 9.4; n=54) points and RULM was a mean increase of 6.4 (SD 6.5; n=54) points at follow up visit day 2070.

Patients randomised to sham in Study CS4 and initiating treatment with SPINRAZA in Study CS11 were of a median age of 4.9 years (range 3.3 to 9.0 years). HFSME change was a mean decrease of 1.3 (SD 9.3; n=22) points and RULM was a mean increase of 4.2 (SD 4.4; n=23) points at follow up visit day 2070.

In contrast, the natural disease course of untreated patients of similar age and clinical characteristics shows a progressive loss of motor function over time, with an estimated mean decline in HFMSE of 5.4 points over a similar period of 5 years.

### *Study CS2 and Study CS12*

The efficacy of SPINRAZA in Type II and Type III SMA patients has also been demonstrated in a longitudinal analysis across 2 open-label studies (Study CS2 and Study CS12). The analysis included 28 patients who received their first dose in Study CS2, and then transferred to the extension phase, Study CS12. In Study CS2, patients received 9 mg doses of SPINRAZA on days 1 and 85, or 3, 6, or 12 mg doses on days 1, 29, and 85. In Study CS12, patients received 12 mg doses of SPINRAZA on Days 1, 169, 351, and 533. The studies enrolled patients who were between 2 to 15 years of age at first dose. Of the 28 patients, 3 were at least 18 years of age at their last study visit. 1 out of 28 patients had 2 SMN2 gene copies, 21 had 3 copies, and 6 had 4 copies. Outcome measures included HFMSE in all patients, and either the ULM test in non-ambulatory patients, or the 6 MWT performed in ambulatory patients.

Patients were assessed over a 3-year treatment period. A sustained improvement was seen in patients with Type II SMA who experienced a mean improvement from baseline HFMSE score of 5.1 (SD 4.05, n=11) at Day 253, and 9.1 (SD 6.61, n=9) at Day 1050. The mean total score was 26.4 (SD 11.91) at Day 253 and 31.3 (SD 13.02) at Day 1050, no plateau was observed. This is in comparison to the decline typically observed in patients with later-onset SMA over time.

Patients with Type III SMA demonstrated a mean improvement from baseline HFSME score of 1.3 (SD 1.87, n=16) at Day 253 and 1.2 (SD 4.64, n=11) at Day 1050. The mean total score was 49.8 (SD 12.46) at Day 253 and 52.6 (SD 12.78) at 1050 days.

In patients with Type II SMA the ULM test was conducted, with mean improvement of 1.9 (SD 2.68, n=11) at Day 253 and 3.5 (SD 3.32, n=9) at Day 1050. The mean total score was 13.8 (SD 3.09) at Day 253 and 15.7 (SD 1.92) at Day 1050. The 6 MWT was conducted for ambulatory patients only. In these patients, a mean improvement of 28.6 metre (SD 47.22, n=12) at Day 253 and 86.5 metres (SD 40.58, n=8) at Day 1050. The mean 6 MWT distance was 278.5 metres (SD 206.46) at Day 253 and 333.6 metres (SD 176.47) at Day 1050. Two previously non-independent ambulatory patients (Type III) achieved independent walking, and one non-ambulatory patient (Type II) achieved independent walking.

**Table 7: Percentages of Patients who achieved Clinically Meaningful Changes in HFMSE, ULM and 6 MWT**

<b>Efficacy Measure</b>	<b>Day 253</b>	<b>Day 1050</b>
HFMSE, $\geq$ 3 points		
Type II, n (%)	9/11 (82%)	7/9 (78%)
Type III, n (%)	3/16 (19%)	4/11 (36%)
ULM, $\geq$ 2 points*		
Type II, n (%)	5/11 (45%)	5/9 (56%)
6 MWT, $\geq$ 30 metres#		
Type III, n (%)	6/12 (50%)	8/8 (100%)

\*6 Type III patients performed the ULM at Day 253 or Day 1050 but are not included in the table because the majority had the maximum score of 18 points at baseline and no patient declined over time

#1 Type II patient developed the ability to walk independently; otherwise, no Type II patients were assessed by the 6 MWT

Patients with infantile- or later-onset SMA

Study SM202 (EMBRACE)

Study SM202 is a phase 2, two-part study of which Part 1 was randomised, double-blind, and sham procedure-controlled and Part 2 was an open label extension. The study enrolled symptomatic patients diagnosed with infantile-onset SMA ( $\leq$  6 months) or later-onset SMA ( $>$  6 months) and 2 or 3 copies of SMN2 who were not eligible for participation in Study CS3B or Study CS4 due to screening age or SMN2 copy number. Patients were followed for a median of 302 days in Part 1 of the study.

All patients treated with SPINRAZA were alive as of the early termination of Part 1, however, one patient in the control arm died at Study day 289. In addition, no patients in the SPINRAZA group or sham-control group required the use of permanent ventilation. Of the 13 patients with infantile-onset SMA, 7/9 (78%; 95% CI: 45, 94) of the SPINRAZA group and 0/4 (0%; 95%CI: 0, 60) of the sham group met the criteria for motor milestone response (HINE Section 2). Of the 8 patients with later-onset SMA, 4/5 (80%; 95% CI: 38, 96) of the SPINRAZA group and 2/3 (67%; 95%: 21, 94) of the sham-control group met this definition of response.

### **Adults**

No controlled clinical data are available.

Real world clinical findings support the effectiveness of nusinersen to stabilise or improve motor function (HFMSE, 6MWT, RULM) in some SMA adult Type II and III patients who initiated nusinersen in adulthood and were followed up over 10 to 14 months. A decline in motor function over time has been reported in untreated SMA patients.

Limited clinical data from an interim analysis from 7 young adults with Type II or III SMA (aged 18.8 – 22.5 years) who initiated treatment during adolescence and who were followed for 5.3 – 6.8 years in the CS2/CS12/SHINE studies indicate a stabilisation or improvement in motor function in these patients as assessed by the 6MWT and HFMSE.

### **Pre-symptomatic infants**

#### *Study CS5/232SM201 (NURTURE)*

Study CS5, is an open-label study in pre-symptomatic infants genetically diagnosed with SMA who were enrolled at 6 weeks of age or younger. Patients in this study were deemed most likely to develop Type I or II SMA. Patients received a 12 mg scaled equivalent dose of SPINRAZA based on CSF volume scaling on study days 1, 15, 29, 64, 183, 302, 421, 540, 659 and 778. Median age at first dose was 22 days (range 3-42 days). At baseline the median number of motor milestones achieved was 3 (range 0-7), the median CHOP-INTEND total score was 50.0 (range 25-60), and the median ulnar CMAP amplitude was 2.65 mV (1.0-6.7).

The interim analysis (cut-off date 19 Feb 2020) was conducted when patients had been on study for a median of 48.3 months (36.6 – 57.1 months) and were of a median age at last visit of 46.0 months (34.0 – 57.0 months). At the time of the interim analysis, all 25 of the patients (2 SMN2 gene copies, n=15; 3 SMN2 gene copies, n=10) are alive without permanent ventilation. The primary endpoint time to death or respiratory intervention (defined as invasive or non-invasive ventilation for  $\geq 6$  hours/day continuously for  $\geq 7$  consecutive days or tracheostomy) could not be estimated as there were too few events. Four patients (2 SMN2 copies) required respiratory intervention  $>6$  hours/day continuously for  $\geq 7$  days, all of whom initiated ventilatory support during an acute reversible illness (see Figure 6).


Patients achieved milestones unexpected in Type I or II SMA and more consistent with normal development. At the interim analysis, all 25 (100%) patients had achieved the WHO motor milestone of sitting without support, 23 (92%) had achieved the ability to walk with assistance and 22 of 25 (88%) had achieved walking alone. 21 (84%) patients achieved the maximum attainable CHOP INTEND score of 64. All patients had maintained the ability to suck and swallow at last visit (Day 788), with 22/25 (88%) infants achieved a maximal score on the HINE Section 1.

The proportion of patients developing clinically manifested SMA was assessed amongst patients who reached the Day 700 (n=25) visit at the interim analysis. The protocol-defined criteria for clinically manifested SMA included age-adjusted weight below the fifth WHO percentile, a decrease of 2 or more major weight growth curve percentiles, the placement of a percutaneous gastric tube, and/or the inability to achieve expected age-appropriate WHO

milestones (sitting without support, standing with assistance, hands-and-knees crawling, walking with assistance, standing alone and walking alone). At Day 700, 7/15 (47%) of patients with 2 SMN2 copies and 0/10 patients with 3 SMN2 copies met the protocol-defined criteria for clinically manifested SMA, however, these patients were gaining weight, and achieving milestones, inconsistent with Type I SMA. A comparison of motor function achievement among the patients with symptomatic infantile-onset SMA and pre-symptomatic SMA is shown in [Figure 8](#) and [Figure 9](#).

As illustrated in Figures 6, 7 and 8, the greatest benefit in overall survival and motor milestones occurred when SPINRAZA treatment was initiated prior to symptom onset.

**Figure 6: Overall Survival Versus Study Days in Study CS3B (treated and sham-control), CS3A, CS5 and CS11 – ITT Set**




	0	1	2	3	4	5	6	7	8
232SM201	15	15	15	15	8				
CS3A	17	13	13	9					
CS3B-active + CS11	81	64	60	60	58	56	52	25	3
CS11 (CS3B-sham)	23	21	21	20	18	16	9		
CS3B-sham	40	11							

Population used in figure: 232SM201: Subjects with SMN2 2 copy in ITT set, CS3A: SMN2 2 copy subjects, CS3B: Subjects with SMN2 2 copy in ITT set.

SOURCE: ISIS396443/ISS/CDS-UPDATE-2024/F-TTE-TIMDTH-CLN.SAS

DATE: 07MAR2024


**Figure 7: Time to Death or Permanent Ventilation Versus Study Days in Study CS3B (treated and sham-control), CS3A, CS5 and CS11: ITT Set**



	Time (years) to Death or Permanent Ventilation									
	0	1	2	3	4	5	6	7	8	9
232SM201	15	15	15	15	8					
CS3A	17	12	11	6						
CS3B-active + CS11	81	42	38	38	37	36	33	15	3	
CS11 (CS3B-sham)	11	6	6	5	5	3	2			
CS3B-sham	40	6								

Population used in figure: 232SM201: Subjects with SMN2 2 copy in ITT set, CS3A: SMN2 2 copy subjects, CS3B: Subjects with SMN2 2 copy in ITT set.  
 Subjects that have already met the permanent ventilation endpoint in the index study are not considered in the CS11 (CS3B-sham) group.  
 SOURCE: ISIS396443/ISS/CDS-UPDATE-2024/F-TTE-TIMDPV-CLN.SAS DATE: 07MAR2024

**Figure 8: Total HINE Motor Milestones Score Versus Study Days for Study CS3B (treated and sham-control, IES), CS3A (IES), CS5 and CS11 (ITT Set)**



Population used in figure: 232SM201 subjects in the ITT set with SMN2 copy number denoted in parentheses, CS3A: SMN2 2 copy subjects, CS3B: Subjects with SMN2 2 copy in ITT set.  
 For CS3A and CS3B the data were windowed into intervals based on time from baseline.  
 For 232SM201 and CS3A, visits with n < 5 are not plotted. For the remaining groups visits with n < 10 are not plotted.  
 SOURCE: ISIS396443/ISS/CDS-UPDATE-2024/F-HMOTOR-BYVIS-GRA-CLN.SAS DATE: 18MAR2024

**Figure 9: Total CHOP INTEND Score by visit day Study CS3B (treated and sham-control), CS3A, CS5 and CS11: ITT Set**



## 5.2 Pharmacokinetic properties

Single and multiple dose pharmacokinetics of nusinersen, administered via intrathecal (IT) injection, were determined in paediatric patients diagnosed with SMA.

### Absorption

Intrathecal injection of nusinersen into the cerebrospinal fluid (CSF) allows nusinersen to be fully available for distribution from the CSF to the target central nervous system (CNS) tissues.

The average increase in trough CSF levels from the start of the maintenance phase through to the last observation timepoint across all patients was approximately 3.2-fold and 2.3-fold in the later-onset and infantile-onset populations respectively. Overall, cumulative CSF PK data collected through to the end of Study CS11 indicated that in infantile and later onset SMA patients, the standard dosing regimen (12 mg every 4 months) leads to a steady state CSF concentration by 7 to 8 years of treatment.

Following IT administration trough plasma concentrations of nusinersen were relatively low compared to the trough CSF concentration. Median plasma  $T_{max}$  values ranged from 1.7 to 6.0 hours. Mean plasma  $C_{max}$  and AUC values increased approximately dose proportionally over the evaluated dose range. There is no accumulation in plasma exposure measures ( $C_{max}$  and AUC) after multiple doses.

### Distribution

Autopsy data from patients ( $n=3$ ) show that nusinersen administered intrathecally is broadly distributed within the CNS achieving therapeutic levels in the target spinal cord tissues. Presence of nusinersen was also demonstrated in neurons and other cell types in the spinal cord and brain, and peripheral tissues such as skeletal muscle, liver, and kidney.

### Biotransformation

Nusinersen is metabolised slowly via exonuclease (3'- and 5')-mediated hydrolysis and is not a substrate for, or inhibitor or inducer of CYP450 enzymes.

### Elimination

The mean terminal elimination half-life in CSF is estimated at 135 to 177 days. The primary route of elimination is likely by urinary excretion of nusinersen and its metabolites.

### Characteristics in specific groups of patients

#### **Renal and hepatic impairment**

The pharmacokinetics of nusinersen in patients with renal impairment or hepatic impairment have not been studied.

#### **Gender**

Population pharmacokinetic analysis shows that gender does not affect the pharmacokinetics of nusinersen.

## 5.3 Preclinical safety data

### Genotoxicity

Nusinersen demonstrated no evidence of genotoxicity in *in vitro* (Ames and chromosomal aberrations in CHO cells) and *in vivo* (mouse micronucleus) assays. However, no assays were

performed to demonstrate nusinersen uptake into bacterial and mammalian cells.

### Carcinogenicity

In a carcinogenicity study in mice, subcutaneous administration of nusinersen for 2 years resulted in an increased incidence of benign uterine haemangioma in female mice at 50 mg/kg every 2 weeks. No significant effects were seen in males at this dose or females at the lower doses of 5 mg/kg and of 15 mg/kg every 2 weeks. The estimated systemic exposures at the no effect levels in both sexes far exceed the expected systemic exposures in patients.

### Toxicology

In repeat-dose toxicity studies (14weeks and 53weeks) of IT administration to juvenile cynomolgus monkeys, nusinersen was well tolerated. The exception was an acute, transient deficit in lower spinal reflexes which occurred at the highest dose levels in each study (3 or 4 mg per dose). These effects were observed within several hours postdose and generally resolved within 48 hours.

## **6. PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

Sodium chloride  
Potassium chloride  
Calcium chloride dihydrate  
Magnesium chloride hexahydrate  
Dibasic sodium phosphate  
Sodium phosphate monobasic dihydrate  
Sodium hydroxide (as required for pH adjustment)  
Hydrochloric acid (as required for pH adjustment)  
Water for injections.

### **6.2 Incompatibilities**

Not applicable.

### **6.3 Shelf life**

5 years

### **6.4 Special precautions for storage**

Store between 2°C to 8°C. Refrigerate. Do not freeze.  
SPINRAZA should be protected from light and kept in the original carton until time of use.

If no refrigeration is available, SPINRAZA may be stored in its original carton, protected from light at or below 30°C for up to 14 days.

Prior to administration, unopened vials of SPINRAZA can be removed from and returned to the refrigerator a total of 5 times, if necessary. If removed from the original carton, the total combined time out of refrigeration and secondary packaging (carton) should not exceed 30 hours, at a temperature that does not exceed 25°C.

Do not dilute. Once drawn into syringe, administer within 6 hours. Discard any unused product. For single use in one patient on one occasion only.

## 6.5 Nature and contents of container

Each pack contains one 5 mL liquid in vial (type 1 glass) with a bromobutyl rubber stopper, an aluminium over-seal and a flip-off plastic cap. Each vial contains 5 mL of a clear and colourless solution, of 12.6 mg nusinersen heptadecasodium, equivalent to 12 mg of nusinersen for intrathecal injection.

## 6.6 Special precautions for disposal

Dispose of all the materials, including any unused solution contained within the vial in accordance with local requirements.

## 7. MEDICINE SCHEDULE

Prescription Medicine

## 8. SPONSOR

Biogen NZ Biopharma Limited  
155 Fanshawe Street  
Auckland  
Tel: 0800 852 289

## 9. DATE OF FIRST APPROVAL

23 August 2018

## 10. DATE OF REVISION OF THE TEXT

17 December 2025

BIOGEN® is a registered trademark of Biogen MA Inc.

## SUMMARY TABLE OF CHANGES

Section Changed	Summary of new information
4.8 Post-marketing experience	Clinical trial exposure data updated to include SHINE data.
5.1 Pharmacodynamic properties	SHINE data updated (for ENDEAR and CHERISH patients only) and NURTURE interim study data. Natural disease course data added.
5.2 Pharmacokinetic properties	Cerebrospinal fluid (CSF) absorption data updated to include SHINE data.
Immunogenicity	SHINE study data and interim NURTURE data updated in

	immunogenicity section. Section relocated from 4.8 Post-marketing experience to 5.1 Immunogenicity.
4.9 Overdose	Update wording